AccessibilityHelp
Baijin Life Science logo

Baijin Life Science(OTC) MNNGF

Market Cap$139.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)+7%
5 Year+1,400%
1 Year+88%
1 Month+88%
$0.15
+0.00%
+0.00Today
Baijin Life Science last closing stock price
MetricPriceDate
Last closeUSD 0.152026-09-16
Baijin Life Science stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+50%USD 0.102026-08-24
1 month+87.5%USD 0.082026-08-06
3 month+100%USD 0.082026-05-29
Year to date+150%USD 0.062025-12-26
1 year+87.5%USD 0.082025-09-08
3 year+87.5%USD 0.082023-08-22
5 year+1,400%USD 0.012021-08-19
Since inception+7.14%USD 0.142015-04-10

Baijin Life Science Financials at a Glance

Market Cap

$139.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

HK$224.81M

Net Income (TTM)

-HK$38.16M

EPS (TTM)

-$0.01

P/E Ratio

-25.86

Dividend

$0.00

Beta (Volatility)

-24.54 (Low)

Price

$0.15

Volume

3,861

Open

$0.15

Previous Close

$0.15

Daily Range

$0.15 - $0.15

52-Week Range

$0.05 - $0.15

Estimated Earnings Date

Nov 29, 2024

MNNGF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Baijin Life Science

Baijin Life Science Holdings Limited is an investment holding company specializing in the pearl and jewelry industry. The company engages in sourcing, processing, design, manufacturing, and wholesale distribution of pearls and jewelry, while also offering strategic investment and financial services.

Products and Services
  • Sale of pearls and jewelry
  • Strategic investment and financial services
  • Real estate financial asset investments
Growth Outlook
  • Expansion into global markets including the US, UK, and China
  • Increased focus on luxury goods sector growth
  • Potential for diversification in financial services
Financial Highlights
  • Recent quarterly revenue of 34.14 million HKD
  • Trailing twelve months (TTM) revenue of 55.11 million HKD
  • Current ratio of 2.97 indicates strong liquidity position
Baijin Life Science Holdings Limited operates in a dynamic industry with a diverse range of products and services. The company's strategic focus on luxury goods and financial services positions it well for future growth. Recent financial performance shows a revenue increase, reflecting the company's ability to adapt and thrive in a competitive market. The strong liquidity position, as indicated by the current ratio, suggests that the company is well-equipped to manage its short-term obligations. Overall, Baijin Life Science Holdings Limited presents an intriguing opportunity for investors interested in the luxury goods sector and financial services.
AI Generated • Oct 5, 2026

Industry

Textiles, Apparel and Luxury Goods

Sector

Consumer Discretionary

Employees

84

CEO

Sau Man Yan

Website

www.affluent-partners.com

Headquarters

Hong Kong, HK

MNNGF Financials

Key Financial Metrics (TTM)

Gross Margin

7.46%

Operating Margin

-37.74%

Net Income Margin

-42.40%

Return on Equity

-23.23%

Return on Capital

-22.49%

Return on Assets

-14.32%

Earnings Yield

-3.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$139.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

932.25M

Volume

3.86K

Avg. Volume

126.631

Financials (TTM)

Gross Profit

HK$48.65M

Operating Income

-HK$50.02M

EBITDA

-HK$17.64M

Operating Cash Flow

-HK$37.57M

Capital Expenditure

-HK$17.84M

Free Cash Flow

-HK$55.52M

Cash & ST Invst.

HK$43.09M

Total Debt

HK$28.40M

Baijin Life Science Performance Analysis

Baijin Life Science annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31HKD 11,083,45037.7%
20242024-03-31HKD 6,859,646-38.1%
20252025-03-31HKD 17,394,274153.6%
20262026-03-31HKD 11,443,196-34.2%
Baijin Life Science sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30148.3%
Q42025-03-31-8.8%
Q22025-09-30-14.8%
Q42026-03-31-38.1%
Baijin Life Science annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31HKD 0.00N/A
20242024-03-31HKD -0.00N/A
20252025-03-31HKD -0.00-93.3%
20262026-03-31HKD -0.015700.0%
Baijin Life Science sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30-16.5%
Q42025-03-31190.2%
Q22025-09-30-62.7%
Q42026-03-31-1996.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

HK$34.14M

+19.6%

Gross Profit

-HK$1.82M

-117.3%

Gross Margin

-5.33%

N/A

Market Cap

$139.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.66M

N/A

Employees

84

N/A

Net Income

-HK$40.02M

-680.1%

EBITDA

-HK$30.24M

-477.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

HK$43.09M

+11.6%

Total Debt

HK$28.40M

-44.5%

Accounts Receivable

HK$59.63M

+275.3%

Inventory

HK$58.25M

+31.4%

Long Term Debt

HK$5.50M

-86.5%

Short Term Debt

HK$22.90M

+117.4%

Return on Assets

-14.32%

N/A

Return on Invested Capital

-16.87%

N/A

Free Cash Flow

-HK$30.60M

-388.8%

Operating Cash Flow

-HK$15.19M

-149.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,623.68-0.01%
^DJIDJI
$52,215.16-0.01%
^IXICNASDAQ
$25,955.34-0.00%
BTCBitcoin
$80,332.00-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About MNNGF

What is the current price of Baijin Life Science?

Baijin Life Science is trading at $0.15 per share.

What is the 52-week range for Baijin Life Science?

Over the past 52 weeks, Baijin Life Science has traded between $0.05 and $0.15.

How much debt does Baijin Life Science have?

As of the most recent reporting period, Baijin Life Science reported total debt of HK$3.62M.

How much cash does Baijin Life Science have on hand?

Baijin Life Science reported HK$5.50M in cash and cash equivalents in its most recent financial results.

What is Baijin Life Science’s dividend yield?

Baijin Life Science does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services